Ryvu Therapeutics SA Cash Flow Conversion Efficiency

Latest as of March 2026: -0.553x

Ryvu Therapeutics SA cash flow conversion efficiency. Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has a cash flow conversion efficiency ratio of -0.553x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-22.84 Million ≈ $-6.29 Million USD) by net assets (zł41.33 Million ≈ $11.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Ryvu Therapeutics SA (2010–2025)

Cash flow conversion efficiency of Ryvu Therapeutics SA from 2010 to 2025. This chart illustrates how Ryvu Therapeutics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ryvu Therapeutics SA stock price for real-time trading data and today's change.

Ryvu Therapeutics SA Cash Flow Conversion Ratio Explained

Ryvu Therapeutics SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Ryvu Therapeutics SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ryvu Therapeutics SA ranked by their cash flow conversion efficiency. Also see RVU market cap overview for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Minerva Neurosciences Inc NASDAQ:NERV	21.365x
Schloss Wachenheim AG F:SWA	-0.008x
CVC Income & Growth Limited LSE:CVCE	0.052x
Taegu Broadcasting Corporation KQ:033830	-0.041x
Thuan Duc JSC VN:TDP	0.282x
AS HARJU ELEKTER EO 063 F:HD8	0.034x
Excel Cell Electronic Co Ltd TW:2483	-0.003x
Asefa Public Company Limited BK:ASEFA	0.121x

Annual Cash Flow Conversion Efficiency for Ryvu Therapeutics SA (2010–2025)

The table below shows the annual cash flow conversion efficiency of Ryvu Therapeutics SA from 2010 to 2025. Review how much free cash does Ryvu Therapeutics SA generate to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	zł70.75 Million ≈ $19.47 Million	zł-110.28 Million ≈ $-30.35 Million	-1.559x	-73.22%
2024-12-31	zł143.88 Million ≈ $39.60 Million	zł-129.48 Million ≈ $-35.63 Million	-0.900x	-176.29%
2023-12-31	zł259.59 Million ≈ $71.44 Million	zł-84.55 Million ≈ $-23.27 Million	-0.326x	-624.62%
2022-12-31	zł343.39 Million ≈ $94.51 Million	zł21.32 Million ≈ $5.87 Million	0.062x	+118.18%
2021-12-31	zł169.42 Million ≈ $46.63 Million	zł-57.87 Million ≈ $-15.93 Million	-0.342x	-618.46%
2020-12-31	zł223.72 Million ≈ $61.57 Million	zł-10.64 Million ≈ $-2.93 Million	-0.048x	+67.28%
2019-12-31	zł119.76 Million ≈ $32.96 Million	zł-17.40 Million ≈ $-4.79 Million	-0.145x	+22.25%
2018-12-31	zł194.86 Million ≈ $53.63 Million	zł-36.42 Million ≈ $-10.02 Million	-0.187x	-208.91%
2017-12-31	zł64.00 Million ≈ $17.61 Million	zł10.98 Million ≈ $3.02 Million	0.172x	+252.23%
2016-12-31	zł55.71 Million ≈ $15.33 Million	zł-6.28 Million ≈ $-1.73 Million	-0.113x	+67.84%
2015-12-31	zł46.88 Million ≈ $12.90 Million	zł-16.43 Million ≈ $-4.52 Million	-0.350x	+33.84%
2014-12-31	zł9.25 Million ≈ $2.55 Million	zł-4.90 Million ≈ $-1.35 Million	-0.530x	+99.76%
2013-12-31	zł3.13 Million ≈ $861.02K	zł-694.94 Million ≈ $-191.26 Million	-222.129x	-13705.80%
2012-12-31	zł5.53 Million ≈ $1.52 Million	zł-8.90 Million ≈ $-2.45 Million	-1.609x	-208.42%
2011-12-31	zł11.46 Million ≈ $3.15 Million	zł-5.98 Million ≈ $-1.65 Million	-0.522x	+78.85%
2010-12-31	zł1.50 Million ≈ $413.48K	zł-3.71 Million ≈ $-1.02 Million	-2.467x	--

About Ryvu Therapeutics SA

WAR:RVU Poland Biotechnology

Market Cap

$108.04 Million

zł392.58 Million PLN

Market Cap Rank

#18711 Global

#142 in Poland

Share Price

zł16.98

Change (1 day)

-4.61%

52-Week Range

zł13.76 - zł29.90

All Time High

zł75.00